$ACT Headlines Options remain limited for growth-stock

New Post Public Reply Private Reply Replies (0) Message Board

Jan 29, 2015 at 12:30 PM

$ACT Headlines

Options remain limited for growth-stock speculators 3:16 p.m. Jan. 22, 2015 - The Trading Deck
These unloved stocks may beat the S&P 500 again in 2015 10:56 a.m. Jan. 20, 2015 - Brett Arends
10 hated stocks your portfolio will love 6:01 a.m. Jan. 20, 2015 - Brett Arends
Actavis expects profit to beat expectations 9:44 a.m. Jan. 12, 2015 - Michael Calia
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
10 stocks that can withstand a rocky 2015 12:31 p.m. Dec. 31, 2014 - The Trading Deck
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt

Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market 8:06 a.m. Today - Seeking Alpha
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog 6:30 p.m. Jan. 28, 2015 - Zacks.com
Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog 5:50 p.m. Jan. 28, 2015 - Zacks.com
Pfizer Sales Hit by Stronger Dollar 6:06 p.m. Jan. 27, 2015 - The Wall Street Journal Interactive Edition
Actavis to Buy Auden Mckenzie, Boost Generic Portfolio - Analyst Blog 6:00 p.m. Jan. 27, 2015 - Zacks.com
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog 4:45 p.m. Jan. 27, 2015 - Zacks.com
Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog 3:20 p.m. Jan. 27, 2015 - Zacks.com
3 Stocks Dragging The Health Care Sector Downward 12:07 p.m. Jan. 27, 2015 - TheStreet.com
Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog 12:00 p.m. Jan. 27, 2015 - Zacks.com
Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog 11:20 a.m. Jan. 27, 2015 - Zacks.com
Citigroup Ponders How Results From Namenda Survey Might Affect Actavis 8:48 a.m. Jan. 27, 2015 - benzinga.com
Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog 4:00 p.m. Jan. 26, 2015 - Zacks.com
Actavis Surges Amid Acquisition Of Auden Mckenzie For £306 Million 10:45 a.m. Jan. 26, 2015 - benzinga.com
Actavis to Buy Auden Mckenzie 8:15 a.m. Jan. 26, 2015 - The Wall Street Journal Interactive Edition
UPDATE: Actavis Reports Purchase of Auden Mckenzie for £306M 6:34 a.m. Jan. 26, 2015 - benzinga.com
Pharmaceuticals Sector To See High Voltage Action in 2015 3:13 p.m. Jan. 23, 2015 - GuruFocus.com
Will Abiomed (ABMD) Outshine Q3 Earnings Estimates? - Analyst Blog 12:40 p.m. Jan. 23, 2015 - Zacks.com
3 Health Care Stocks Driving The Sector Higher 12:03 p.m. Jan. 23, 2015 - TheStreet.com
Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst Blog 11:30 a.m. Jan. 23, 2015 - Zacks.com
Top World Stocks Close In On Buy Points, New Highs 5:36 p.m. Jan. 22, 2015 - Investors Business Daily

Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC 5:30 p.m. Jan. 26, 2015 - BusinessWire - BZX
Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC 5:30 p.m. Jan. 26, 2015 - PR Newswire - PRF
Actavis to Acquire Auden Mckenzie for 306M GBP 7:30 a.m. Jan. 26, 2015 - PR Newswire - PRF
Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia 2:00 a.m. Jan. 20, 2015 - PR Newswire - PRF
Actavis Launches U.S. Generic Specialty Injectable Portfolio 8:00 a.m. Jan. 13, 2015 - PR Newswire - PRF
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom 8:35 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance 8:30 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR 3:54 p.m. Jan. 6, 2015 - PR Newswire - PRF
Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 2:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...